145 related articles for article (PubMed ID: 11571736)
1. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma.
Thylén A; Hjerpe A; Martensson G
Cancer; 2001 Sep; 92(5):1224-30. PubMed ID: 11571736
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical differences between hyaluronan- and non-hyaluronan-producing malignant mesothelioma.
Thylén A; Levin-Jacobsen AM; Hjerpe A; Martensson G
Eur Respir J; 1997 Feb; 10(2):404-8. PubMed ID: 9042640
[TBL] [Abstract][Full Text] [Related]
3. High CD44 expression on human mesotheliomas mediates association with hyaluronan.
Penno MB; Askin FB; Ma H; Carbone M; Vargas MP; Pass HI
Cancer J Sci Am; 1995; 1(3):196-203. PubMed ID: 9166476
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.
Hiraki A; Aoe K; Murakami T; Nakamura Y; Yamazaki K; Sueoka N; Taguchi K; Kamei T; Maeda T; Takeyama H; Kishimoto T; Nishimura M; Sugi K
Oncol Rep; 2005 Aug; 14(2):357-62. PubMed ID: 16012715
[TBL] [Abstract][Full Text] [Related]
5. The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion.
Dejmek A; Hjerpe A
Diagn Cytopathol; 2005 Mar; 32(3):160-6. PubMed ID: 15690331
[TBL] [Abstract][Full Text] [Related]
6. Stimulatory effects of pleural fluids from mesothelioma patients on CD44 expression, hyaluronan production and cell proliferation in primary cultures of normal mesothelial and transformed cells.
Teder P; Versnel MA; Heldin P
Int J Cancer; 1996 Jul; 67(3):393-8. PubMed ID: 8707414
[TBL] [Abstract][Full Text] [Related]
7. Hyaluronan in pleural effusions and in serum.
Hillerdal G; Lindqvist U; Engström-Laurent A
Cancer; 1991 May; 67(9):2410-4. PubMed ID: 2013045
[TBL] [Abstract][Full Text] [Related]
8. Advances in the biology of malignant pleural mesothelioma.
Zucali PA; Ceresoli GL; De Vincenzo F; Simonelli M; Lorenzi E; Gianoncelli L; Santoro A
Cancer Treat Rev; 2011 Nov; 37(7):543-58. PubMed ID: 21288646
[TBL] [Abstract][Full Text] [Related]
9. Higher concordance of PD-L1 expression between biopsies and effusions in epithelioid than in nonepithelioid pleural mesothelioma.
Mansour MSI; Seidal T; Mager U; Dobra K; Brunnström H; Dejmek A
Cancer Cytopathol; 2021 Jun; 129(6):468-478. PubMed ID: 33493383
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma.
Ceresoli GL; Locati LD; Ferreri AJ; Cozzarini C; Passoni P; Melloni G; Zannini P; Bolognesi A; Villa E
Lung Cancer; 2001 Nov; 34(2):279-87. PubMed ID: 11679187
[TBL] [Abstract][Full Text] [Related]
11. Effects of hyaluronic acid and CD44 interaction on the proliferation and invasiveness of malignant pleural mesothelioma.
Hanagiri T; Shinohara S; Takenaka M; Shigematsu Y; Yasuda M; Shimokawa H; Nagata Y; Nakagawa M; Uramoto H; So T; Tanaka F
Tumour Biol; 2012 Dec; 33(6):2135-41. PubMed ID: 22886525
[TBL] [Abstract][Full Text] [Related]
12. Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients.
Fusco V; Ardizzoni A; Merlo F; Cinquegrana A; Faravelli B; De Palma M; Chessa L; Nicolò G; Serra M; Capaccio A
Anticancer Res; 1993; 13(3):683-9. PubMed ID: 8317897
[TBL] [Abstract][Full Text] [Related]
13. The sensitivity of hyaluronan analysis of pleural fluid from patients with malignant mesothelioma and a comparison of different methods.
Martensson G; Thylen A; Lindquist U; Hjerpe A
Cancer; 1994 Mar; 73(5):1406-10. PubMed ID: 8111707
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of pleural fluid pH in malignant epithelial mesothelioma after talc poudrage.
Aelony Y; Yao JF; King RR
Respiration; 2006; 73(3):334-9. PubMed ID: 16679752
[TBL] [Abstract][Full Text] [Related]
15. Cytokeratin 19 fragment/carcinoembryonic antigen ratio in pleural effusion is a useful marker for detecting malignant pleural mesothelioma.
Suzuki H; Hirashima T; Kobayashi M; Sasada S; Okamoto N; Uehara N; Tamiya M; Matsuura Y; Morishita N; Kawase I
Anticancer Res; 2010 Oct; 30(10):4343-6. PubMed ID: 21036761
[TBL] [Abstract][Full Text] [Related]
16. Pleural fluid analysis in malignant mesothelioma. Prognostic implications.
Gottehrer A; Taryle DA; Reed CE; Sahn SA
Chest; 1991 Oct; 100(4):1003-6. PubMed ID: 1914546
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors and survival in malignant pleural mesothelioma.
Van Gelder T; Damhuis RA; Hoogsteden HC
Eur Respir J; 1994 Jun; 7(6):1035-8. PubMed ID: 7925870
[TBL] [Abstract][Full Text] [Related]
18. Assessment of interferon-γ in pleural fluid as a prognostic factor of survival in malignant pleural mesothelioma.
Dozin B; Carbotti G; Roncella S; Ferro P; Dessanti P; Canessa PA; Ferrini S; Fabbi M
Cancer Immunol Immunother; 2021 Nov; 70(11):3349-3355. PubMed ID: 34003301
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations.
Rena O; Boldorini LR; Gaudino E; Casadio C
J Surg Oncol; 2011 Nov; 104(6):701-5. PubMed ID: 21437912
[TBL] [Abstract][Full Text] [Related]
20. CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.
Cortes-Dericks L; Schmid RA
Respir Res; 2017 Apr; 18(1):58. PubMed ID: 28403901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
